Business

Swedish contract developer and manufacturer Recipharm says that it has borrowed €90 million from Swedbank AB in order to finance additional contract pharmaceutical manufacturing capacity and acquisitions. The company says that it also plans to use a portion of the funding for "building and enhancing existing and new customer relationships." Recipharm has a dedicated … [Read more...] about Recipharm borrows €90 million to finance expansion

Inhaled drug developer Prosonix has announced the second closing of its Series B equity financing round, which was extended to £17.1M. A new investor, Gimv, added £5.7M to the funds from original syndicate members Ventech, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth, and Solon Ventures. Gimv Venture Capital Partner Karl Nägler will join the … [Read more...] about Prosonix closes Series B financing round

Pearl Therapeutics has won a 2012 TiE50 award from the Indus Entrepreneurs (TiE). Pearl was one of ten winners in the life sciences category. Pearl develops inhaled therapies based on its proprietary particle engineering technology. Pearl CEO Chuck Bramlage said, “The TiE organization awards start-ups that put a premium on entrepreneurial spirit, technological … [Read more...] about Pearl Therapeutics wins technology award

The US Patent and Trade Office has awarded a second patent, to Aegis Therapeutics for stabilized formulations of parathyroid hormone and parathyroid hormone analogs. The new patent (US Patent No. 8,173,594) covers formulations for both injection and nasal delivery that use Aegis's Intravail and ProTek excipients. Both patents have been licensed to Azelon … [Read more...] about Aegis gets second patent for intranasal parathyroid hormone formulations

Rigel Pharmaceuticals says that it plans to focus its efforts on two inhaled asthma therapies: R343, an inhaled SYK inhibitor and R256, an inhaled IL13 signaling/JAK inhibitor. A Phase 2 clinical study of R343 will begin later this summer in mild to moderate asthma patients. Rigel said that it plans to initiate a preclinical development program for R256 but did not … [Read more...] about Rigel advances development of its inhaled SYK inhibitor and inhaled IL13 signaling/JAK inhibitor

Inhaler testing equipment company Copley Scientific has entered into distribution agreements with companies in Turkey and Brazil and now has a Chinese sales and technical support representative in Nanjing, China. Copley sells a range of inhaler testing products, including impactors, delivered dose sampling apparatus, breath simulators, and proprietary inhaler testing … [Read more...] about Copley Scientific establishes distributors in Turkey, Brazil, and China

Texas-based biotechnology company Pulmotect has been granted an award of $7.1 million by the Cancer Prevention & Research Institute of Texas (CPRIT) for development of its lead product PUL-042, an inhaled immune stimulant composed of two synthetic toll-like receptor agonists. The award is intended to fund preclinical, Phase 1, and Phase 2 studies of the product for … [Read more...] about Pulmotect gets $7.1 million for inhaled immune system stimulant

The non-profit patient education organization Allergy & Asthma Network Mothers of Asthmatics (AANMA) has announced the winners of its 2012 Top Ten Innovations in Technology Awards for "products and services that have meaningfully improved quality of life for people with allergies, asthma and related conditions." Of the ten winners, seven are OINDPs. AANMA Founder … [Read more...] about AANMA announces winners of Innovations in Technology awards